These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20190463)

  • 1. Humanized gene replacement in mice reveals the contribution of cancer stroma-derived HB-EGF to tumor growth.
    Ichise T; Adachi S; Ohishi M; Ikawa M; Okabe M; Iwamoto R; Mekada E
    Cell Struct Funct; 2010; 35(1):3-13. PubMed ID: 20190463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers.
    Murata T; Mizushima H; Chinen I; Moribe H; Yagi S; Hoffman RM; Kimura T; Yoshino K; Ueda Y; Enomoto T; Mekada E
    Cancer Res; 2011 Nov; 71(21):6633-42. PubMed ID: 22009535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
    Yagi H; Yotsumoto F; Miyamoto S
    Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
    Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
    Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
    Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectodomain shedding of HB-EGF: a potential target for cancer therapy.
    Miyazono K
    J Biochem; 2012 Jan; 151(1):1-3. PubMed ID: 21976708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
    Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

  • 15. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
    Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro.
    Duque JL; Adam RM; Mullen JS; Lin J; Richie JP; Freeman MR
    J Urol; 2001 Jan; 165(1):284-8. PubMed ID: 11125426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor.
    Kuo PL; Huang MS; Cheng DE; Hung JY; Yang CJ; Chou SH
    J Biol Chem; 2012 Mar; 287(13):9753-9764. PubMed ID: 22291012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
    Clapéron A; Mergey M; Aoudjehane L; Ho-Bouldoires TH; Wendum D; Prignon A; Merabtene F; Firrincieli D; Desbois-Mouthon C; Scatton O; Conti F; Housset C; Fouassier L
    Hepatology; 2013 Dec; 58(6):2001-11. PubMed ID: 23787814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.
    Miyamoto S; Yagi H; Yotsumoto F; Kawarabayashi T; Mekada E
    Cancer Sci; 2006 May; 97(5):341-7. PubMed ID: 16630129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.